HORSHAM, Pa–(BUSINESS WIRE)–Clinical Ink, a global clinical trial technology company, today announced the hiring of Janette Morgan as EVP, General Manager, EMEA. In this unique, hybrid role, Janette will manage the company’s dramatic global growth, blending a focus on both commercial and study operations, while building out an international team to support Clinical Ink’s customers.
“Clinical Ink is hyper-focused on delivering results for our customers,” said Clinical Ink CEO Ed Seguine. “While our primary competitors are focused on concocting their next stage of funding, Clinical Ink is hiring the best people in the industry to better deliver for our customers. As a profitable, mature company and undisputed eSource leader, we are building out our global customer support infrastructure to ensure our explosive growth does not outstrip our ability to provide unparalleled customer service. Janette brings tremendous expertise to our executive team and is the right person to build out our international operations.”
“I believe Clinical Ink’s technology platform and service-first approach will solve the industry’s biggest problems now and into the future,” said Janette. “I’m excited to ensure our customers have solutions to the dynamic clinical and operational challenges that have afflicted this industry for so long. Joining Clinical Ink is an expression of my optimism about the future, and I look forward to collaborating and partnering with our customers to confidently address the great potential for technology to improve the clinical trial experience for patients and sites.”
Prior to joining Clinical Ink, Janette was at Medidata Solutions for 13 years in a variety of roles and worked for a number of eCOA technology providers in the earlier part of her career. Most recently, she was Vice President, Global Partner Initiatives & Partner Business Management, where she was responsible for the global leadership and management of Medidata’s Partner Study-by-Study Business. Working with CRO partners on a global scale from proposal through to contract execution, Janette was instrumental in the transformation of strategy, processes, and GTM approach to address the needs of the most demanding pharma and biotech customers.
Clinical Ink’s Lunexis platform collects clinical trial data from patients and clinicians, at home and on-site. In the past three years, project bookings have tripled, revenue more than quadrupled, and backlog has grown by 500%. Clinical Ink has conducted hundreds of clinical trials on the Lunexis decentralized trial platform, capturing data from patients where they live — everywhere from villages in West Africa, mountaintops in Nepal, nursing homes in Europe, and patient homes in 60+ countries. Lunexis began as a way to transition sites from EDC to DDC (eSource) and to enable easier patient participation at home with BYOD ePRO+. It now offers Build Your Own Study capabilities for sponsors and CROs to have greater control over study design and execution.
About Clinical Ink
Clinical Ink, a global clinical technology company, offers data certainty from source to submission via our Lunexis eSource clinical technology and configurable direct data capture, eCOA, ePRO+, and eConsent modules. This suite of solutions for capturing and integrating electronic data from sites, clinicians, patients, and caregivers at its source naturally enhances clinical trial workflows. For virtual, traditional, or hybrid trials, Lunexis technology reduces manual labor and associated delays, and provides anytime, anywhere data access, saving resources as your trials progress. For more information, visit clinicalink.com.